MedTrace Logo

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

NCT01144143 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-02-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if an anti-inflammatory drug, called infliximab, will reduce inflammation in the synovial lining in patients with an early stage of osteoarthritis of the knee. It will also help determine if the study medication decreases the accumulation of synovial fluid and prevents cartilage breakdown.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

Infliximab

the study drug will be injected into the joint through a needle

DRUG

Placebo

the placebo will be injected into the joint through a needle

DRUG

Standard of Care: Methylprednisolone acetate

Methylprednisolone acetate will be injected into the joint through a needle

Sponsors & Collaborators

  • Centocor, Inc.

    collaborator INDUSTRY

  • Herbert Lindsley, MD

    lead OTHER

Principal Investigators

  • Herbert Lindsley, MD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144143 on ClinicalTrials.gov